Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

The study population is patients with Stage IA endometrial adenocarcinoma with no myometrial invasion or less than 1/2 myometrial invasion. The sample size is 57 cases (Myometrial invasion group : No myometrial invasion group = 1 : 2). Follow up every 3-6 months until the end of the fifth year of treatment. The primary outcome measure is the complete remission rate after 9 months of treatment. Secondary outcome measures include complete remission rate (6 months/12 months after initial treatment), complete remission time, recurrence rate (1 year/2 years after complete remission), recurrence time, pregnancy rate (1 year after complete remission), pregnancy outcome, blood molecular biomarkers, pathological markers, adverse reactions, etc.

Inclusion criteria

• Stage IA (FIGO 2009) ;
• Pathological diagnosis: endometrial adenocarcinoma G1-G2;
• MRI or ultrasound: tumor limited to endometrium or invading less than 1/2 of myometrium；
• 18 years old ≤ Age ≤ 45 years old;
• With a strong desire for fertility preservation；
• Sign the informed consent.

Exclusion criteria

• Complicated with any other malignancy；
• Contraindications to conservative treatment；
• Contraindications to progestin use;
• Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.